Pfizer

Pfizer FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pfizer (PFIZER.NS) as of Sep 26, 2026 is 82.28 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 43.15 % — a change of 90.68% (higher).

FCF Conversion

82.28 %

YoY

90.68%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pfizer is 2026 82.28 % . FCF Conversion Rate (FCF/EBITDA) of Pfizer was 2025 43.15 % . It decreases by 90.68% higher compared to the previous year.

The Pfizer FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
63.62 INR
Jan 1, 2019
21.75 INR
Jan 1, 2020
55.94 INR
Jan 1, 2021
82.32 INR
Jan 1, 2022
106.40 INR
Jan 1, 2023
46.59 INR
Jan 1, 2024
43.15 INR
Jan 1, 2025
82.28 INR
The Pfizer FCF Conversion history
YEARFCF ConversionYoY
82.28 %+90.68%
43.15 %-7.38%
46.59 %-56.21%
106.40 %+29.25%
82.32 %+47.16%
55.94 %+157.22%
21.75 %-65.82%
63.62 %-29.40%
90.12 %-8.93%
98.95 %-72.39%
358.34 %+517.30%
58.05 %—
Access this data via the Eulerpool API

Pfizer Stock analysis

What does Pfizer do? Pfizer Ltd is a global biopharmaceutical company based in New York City, USA. The company was founded in 1849 by cousins Charles Pfizer and Charles Erhart, and has achieved numerous milestones in the pharmaceutical industry during its 170-year history. Pfizer's business model is based on the research, development, production, and distribution of innovative drugs and vaccines for a variety of diseases. With a diverse portfolio of products, the company's range extends from drugs for cancer, inflammation, and immunology to neurological and cardiology conditions. Pfizer is a global leader in the development of cancer drugs and has achieved groundbreaking research successes in recent years. Key divisions of the company include oncology, pain management, cardiology, and neurology. Pfizer places great emphasis on putting patients and their needs at the center and works closely with medical professionals, patient groups, and authorities to ensure the best possible patient care. Pfizer is a leading provider of vaccines and has achieved significant breakthroughs in the development of COVID-19 vaccines in recent years. In December 2020, the company was one of the first worldwide to bring a vaccine against the coronavirus to market, making a significant contribution to the fight against the pandemic. In addition to drug research and development, Pfizer is also heavily involved in corporate social responsibility. The company is committed to sustainable development and continuously works to reduce its carbon footprint. The Pfizer Foundation also supports numerous nonprofit organizations and projects in the areas of health, education, and environmental protection. Among Pfizer's most well-known products are medications such as Viagra, Lipitor, and Lyrica, as well as the COVID-19 vaccine Comirnaty. Pfizer has offices in over 150 countries and employs over 90,000 people worldwide. Like any global company, Pfizer faces challenges. The company is often criticized for high drug prices and the availability of medications in developing countries. However, Pfizer actively advocates for access to affordable healthcare and delivers drugs and vaccines to all regions of the world. Overall, Pfizer is a company of great importance in the global healthcare industry. Through its research and development of innovative drugs and vaccines, the company contributes to improving the quality of life for millions of people worldwide. Pfizer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pfizer stock

FCF Conversion Rate (FCF/EBITDA) of Pfizer is 82.28 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Pfizer changed from 43.15 % to 82.28 %, representing a 90.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pfizer since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pfizer with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Pfizer

All Key Metrics — Pfizer